Change over period: —
NSE · KREBSBIO
KREBS BIOCHM
-17.2% from the 52-week high · +48.4% above the low
Krebs Biochemicals & Industries Ltd. engages in the manufacture and sale of pharmaceutical ingredients and intermediates. The company is headquartered in Hyderabad, Telangana. The firm develops commercially viable biotech processes for application in medicine, agriculture and industry. The company is also engaged in chemical synthesis, fermentation and enzymatic technologies. The company manufactures various products, such as Androstenedione for use as steroid intermediate, and Lovastatin and Simvastatin for anti-cholesterol. The company also undertakes contract manufacturing for pharmaceutical and multinational companies and developing products for sale in global markets. The company has also products in the pilot or research and development stages, which include Amlodipine, Cetirizine, Orlistat, Serratiopepetidase, Telmisartan and Phenylephrine. The company has two manufacturing facilities, one is located at Regadichelaka, Nellore District, and another one located at Kothapalli Village, Kasimkota Mandal, Visakhapatnam District, Andhra Pradesh, India.
The short version. Promoter holding was 72.74% in Sep 2026, up 0.00 points over 8 quarters.
1 · The price
How has the stock traded?
KREBS BIOCHM trades 17.2% below its 52-week high and 48.4% above its 52-week low.
4 · The owners
Who holds it, and are they adding?
Unchanged over 8 quarters.
Unchanged over 8 quarters.
+0 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 72.74 | 72.74 | 72.74 | 72.74 | 72.74 | 72.74 | 72.74 | 72.74 | 0.0 |
| FII | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 26.76 | 26.76 | 26.76 | 26.76 | 26.76 | 26.76 | 26.76 | 26.76 | 0.0 |
Mutual fund holdings · Oct 2026
0 schemes hold this stock
0 the month before.
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for KREBS BIOCHM are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about KREBS BIOCHM
What is the KREBS BIOCHM share price?
KREBS BIOCHM (KREBSBIO) last closed at ₹57.15, down 3.12% on the day. Its 52-week range is ₹39.75 to ₹71.28.
What is the market cap of KREBS BIOCHM?
KREBS BIOCHM has a market capitalisation of about ₹125 crore.
How are KREBS BIOCHM's latest results?
Promoter holding was 72.74% in Sep 2026, up 0.00 points over 8 quarters.
Who owns KREBS BIOCHM?
As of Sep 2026, shareholding was: Promoter 72.74%, FII 0.5%, Public 26.76%.
How many mutual funds hold KREBS BIOCHM?
0 mutual fund schemes held KREBS BIOCHM in October 2026. That compares with 0 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 31 Jan 2019 · Rights issue 21:100
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.